From WikiProjectMed
Jump to navigation Jump to search

Metaraminol Structural Formulae.png
Clinical data
Trade namesAramine, Metaramin, Pressonex
AHFS/Drugs.comInternational Drug Names
License data
  • AU: C
Routes of
Intravenous, endotracheal
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding~45%
  • (1R,2S)-3-[-2-amino-1-hydroxy-propyl]phenol
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass167.208 g·mol−1
3D model (JSmol)
  • O[C@H](c1cc(O)ccc1)[C@@H](N)C
  • InChI=1S/C9H13NO2/c1-6(10)9(12)7-3-2-4-8(11)5-7/h2-6,9,11-12H,10H2,1H3/t6-,9-/m0/s1 checkY
 ☒NcheckY (what is this?)  (verify)

Metaraminol, previously sold under the brand name Aramine among others and also known as metaradrine, is a stereoisomer of meta-hydroxynorephedrine (3,β-dihydroxyamphetamine), is a potent sympathomimetic amine used in the prevention and treatment of hypotension, particularly as a complication of anesthesia. It is an α1-adrenergic receptor agonist with some β effect.[2] It is currently sold in its generic form by Slayback Pharma.[3]

Pharmacology and use as a vasopressor

Metaraminol is given intravenously as either a bolus (often 0.5-1mg doses) or as an infusion, usually via peripheral intravenous access. Metaraminol is commonly available as 10mg in 1mL, that requires dilution prior to administration (often made up to a 0.5mg/mL solution), however pre-prepared syringes of metaraminol for bolus use for hypotension are also commonly available.[4][5]

A commercially prepared pre-filled syringe of metaraminol for bolus use during anaesthesia, made up as 0.5mg/mL (2.5mg in 5mL).


The dominant mechanism for the vasopressor action of metaraminol is indirect,[6] with metaraminol displacing noradrenaline from neuronal vesicles in order to for the noradrenaline to exert its vasopressor action.[7] Metaraminol at higher doses may have direct alpha-adrenergic agonist and beta-1 adrenergic agonist effects.[6] However at doses common in clinical practice, the indirect alpha-1 adrenergic effects predominate, such that reflex bradycardia is a common side-effect.


Metaraminol is also used in the treatment of priapism.[8][9][10]


  1. ^ "Injection : Aramine (Metaraminol Bitartrate)" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 12 March 2022.
  2. ^ Kee VR (August 2003). "Hemodynamic pharmacology of intravenous vasopressors". Crit Care Nurse. 23 (4): 79–82. doi:10.4037/ccn2003.23.4.79. PMID 12961786.
  3. ^ "ANDA APPROVAL FOR METARAMINOL" (PDF). United States Food and Drug Administration. 24 August 2021. Retrieved 13 August 2022.{{cite web}}: CS1 maint: url-status (link)
  4. ^ "Metaraminol 0.5 mg/ml, Solution for Injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc)". Retrieved 19 October 2022.
  5. ^ Goodrick, Nathan; Wentrup, Torben; Messer, Geoffrey; Gleeson, Patricia; Culwick, Martin; Goulding, Genevieve. "Pre-filled emergency drugs: The introduction of pre-filled metaraminol and ephedrine syringes into the main operating theatres of a major metropolitan centre". Australasian Anaesthesia (2013): 127–134.
  6. ^ a b "Metaraminol | Deranged Physiology". Retrieved 19 October 2022.
  7. ^ HARRISON, DONALD C. (1 September 1963). "Studies on the Mechanism of Action of Metaraminol (Aramine)". Annals of Internal Medicine. 59 (3): 297. doi:10.7326/0003-4819-59-3-297. ISSN 0003-4819.
  8. ^ McDonald M, Santucci R (2004). "Successful management of stuttering priapism using home self-injections of the alpha-agonist metaraminol". Int Braz J Urol. 30 (2): 121–2. doi:10.1590/S1677-55382004000200007. PMID 15703094.
  9. ^ Koga S, Shiraishi K, Saito Y (1990). "Post-traumatic priapism treated with metaraminol bitartrate: case report". J Trauma. 30 (12): 1591–3. doi:10.1097/00005373-199012000-00029. PMID 2258979.
  10. ^ Block T, Sturm W, Ernst G, Staehler G, Schmiedt E (1988). "[Metaraminol in therapy of various forms of priapism]". Urologe A. 27 (4): 225–9. PMID 3140463.

External links